Brokerages Set United Therapeutics Co. (NASDAQ:UTHR) Target Price at $370.86

Shares of United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fifteen ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $370.86.

Several equities research analysts have issued reports on the stock. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. TD Cowen raised their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a research note on Monday, October 21st. Argus increased their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH upped their price target on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Finally, HC Wainwright lifted their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a report on Thursday, October 31st.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 15,000 shares of the company's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $1,034,510.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, COO Michael Benkowitz sold 15,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $401.44, for a total value of $6,021,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $1,034,510.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO James Edgemond sold 7,802 shares of the business's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $345.41, for a total value of $2,694,888.82. Following the transaction, the chief financial officer now directly owns 3,210 shares of the company's stock, valued at $1,108,766.10. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 96,422 shares of company stock valued at $35,251,428. 11.90% of the stock is owned by insiders.

Institutional Trading of United Therapeutics

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC lifted its position in United Therapeutics by 1.1% in the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company's stock valued at $692,748,000 after acquiring an additional 22,978 shares in the last quarter. LSV Asset Management lifted its holdings in shares of United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company's stock valued at $307,837,000 after purchasing an additional 436,851 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of United Therapeutics by 4.0% during the second quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company's stock valued at $186,656,000 after buying an additional 22,683 shares during the last quarter. Pacer Advisors Inc. raised its position in United Therapeutics by 19.6% in the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company's stock valued at $178,972,000 after buying an additional 92,240 shares during the last quarter. Finally, Swedbank AB purchased a new stake in United Therapeutics in the 1st quarter valued at $97,316,000. Institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Up 1.8 %

Shares of NASDAQ UTHR traded up $7.43 during mid-day trading on Friday, hitting $410.00. 498,743 shares of the company traded hands, compared to its average volume of 356,442. United Therapeutics has a 1 year low of $208.62 and a 1 year high of $417.82. The stock has a market capitalization of $18.31 billion, a price-to-earnings ratio of 18.01, a PEG ratio of 1.20 and a beta of 0.56. The business has a 50 day moving average of $359.20 and a two-hundred day moving average of $322.77.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to analysts' expectations of $722.62 million. During the same quarter last year, the firm earned $5.38 earnings per share. The business's revenue for the quarter was up 22.9% on a year-over-year basis. As a group, research analysts anticipate that United Therapeutics will post 25.1 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.